A hallmark of HF is the enhanced production of BNP from the heart with increased circulating BNP molecular forms, such as BNP and NT-proBNP, which are specific biomarkers for diagnosis and prognosis in human HF. However, the biological significance of the elevation in circulating BNP has raised questions about the BNP system in HF. 12 We have reported that despite an elevation in immunoreactive BNP1-32, the active form of BNP, as measured by point-of-care testing in subjects with HF and New York Background-We have reported that pro-B-type natriuretic peptide (BNP)-1-108 circulates and is processed to mature BNP1-32 in human blood. Building on these findings, we sought to determine whether proBNP1-108 processed forms in normal circulation are biologically active and stimulate cGMP, and whether proBNP1-108 processing and activity are altered in human heart failure (HF) compared with normal. Because BNP1-32 is deficient whereas proBNP1-108 is abundant in HF, we hypothesize that proBNP1-108 processing and degradation are impaired in HF patients ex vivo. Methods and Results-We measured circulating molecular forms, including BNP1-32, proBNP1-108, and N-terminal-proBNP, and all were significantly higher in patients with HF when compared with that in normals. Fresh serum samples from normals or patients with HF were incubated with or without exogenous nonglycosylated proBNP1-108 tagged with 6 C-terminal Histidines to facilitate peptide isolation. His-tag proBNP1-108 was efficiently processed into BNP1-32/3-32 at 5 minutes in normal serum, persisted for 15 minutes, then disappeared. Delayed processing of proBNP1-108 was observed in HF samples, and the degradation pattern differed depending on left ventricular function. The 5-minute processed forms from both normal and HF serums were active and generated cGMP via guanylyl cyclase-A receptors; however, the 180-minute samples were not active. The proBNP1-108 processing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced in HF versus normal, perhaps contributing to differential BNP metabolism in HF. Conclusions-Exogenous proBNP1-108 is processed into active BNP1-32 and ultimately degraded in normal circulation.
T he endogenous cardiac hormone, B-type natriuretic peptide (BNP), possesses cardiovascular and renal protective actions through guanylyl cyclase receptors (GC)-A. 1 In human heart failure (HF), BNP plays important roles in reducing preload to the heart by natriuresis and vasodilatation and in protecting against cardiac remodeling, especially prior to the activation of the renin-angiotensin-aldosterone system. The conventional concept is that BNP is produced in cardiac cells as proBNP1-108 and is secreted into the circulation as a mature peptide. After signal peptides cleavage from prep-roBNP1-134, the proBNP1-108 is cleaved by proteases to active states. 2 ProBNP1-108 is cleaved into N-terminal (NT)-proBNP1-76 and BNP1-32 by corin 3 and furin. 4 The active BNP1-32 can then be degraded to BNP3-32 by dipeptidyl peptidase-4 (DPPIV), 5, 6 to BNP5-32 by neutral endopeptidase (neprilysin), 7 and to smaller degradation peptides by other enzymes including insulin-degrading enzyme. [8] [9] [10] BNP3-32 has cGMP-generating capabilities in human cell lines 11 ; however, it has reduced cardiorenal actions when compared with BNP1-32 in vivo in normal canines. 6 Thus, it would be important to understand the patterns of BNP molecular forms and their activity in physiological versus pathophysiological states.
Heart Association class IV symptoms, quantitative mass spectral analysis demonstrated an absence of biologically active BNP1-32. 13 Recent investigations have demonstrated reduced biological activities with other molecular forms of BNP, which contribute to the increased BNP immunoreactivity. 11, 14 Also, we reported that in HF much of plasma BNP immunoreactivity measured by commonly used assays is due to altered circulating molecular forms with reduced cGMP-activating properties. 13, 15 Studies suggest that the major nonbiologically active BNP form in plasma of patients with HF is proBNP1-108, 16 and we have recently reported that proBNP1-108 is present in the circulation of normal humans, 17 and that circulating proBNP1-108 predicts adverse cardiovascular outcomes in the general population. 18 The impairment in processing of proBNP1-108 into active BNP1-32 may play a key role in HF. To understand the role of proBNP1-108 processing and activation in normal and HF circulation better, we examined circulating BNP molecular forms and the timing of processing of proBNP1-108 in normal and HF circulation ex vivo, then examined any processed forms for biological activity. We hypothesized that circulating proBNP1-108 levels would be high, and processing of proBNP1-108 would be impaired in HF, by failure to process, delayed processing, or processing to inactive forms. We also hypothesized that proBNP1-108-processing enzyme corin and BNP1-32-degrading enzyme DPPIV circulating levels would be altered in HF.
Methods
All human experimental protocols used in the current study were approved by the Institutional Review Board at Mayo Clinic.
Study Population and Blood Sampling
Studies were performed on blood samples from healthy residents (normals) of Olmsted County, MN, without cardiovascular, renal, pulmonary disease, or diabetes mellitus and patients with HF, New York Heart Association class II to IV, which were obtained at admission to the emergency room or clinic. Samples were collected, immediately stored on ice and examined, or stored at −80°C until measured.
Immunoprecipitation and Western Blot of Histidine-Tagged ProBNP1-108 in Human Serum
Fresh serum samples, with or without proBNP1-108 added, were incubated for varying time points ≤180 minutes at 37°C. His-tag proBNP1-108 (nonglycosylated form; Abcam, Cambridge, MA) is a recombinant fusion protein with 6 histidines added to the C Figure 1 . Pro-B-type natriuretic peptide (proBNP)-1-108 processing and degradation in normal human serum ex vivo. A, A schema of ex vivo study method. Exogenous proBNP1-108 was incubated in fresh human serum for indicated times at 37°C. Unprocessed or processed proBNP1-108 were isolated by immunoprecipitation using His-tag beads and detected by Western blot (WB) with 6xHis antibody. B, Representative WB for His-tag proBNP1-108 incubated in serum samples from normal subjects for indicated times. C and D, Densitometric analysis of unprocessed proBNP1-108 (C) and processed form (BNP1-32/3-32; D) at indicated times. Values are mean±SEM. *P<0.05 vs 0 minutes, 1-way ANOVA with Bonferroni multiple comparison test. terminus ( Figure 1A ). After incubation, His-tag proBNP1-108 (500 ng/100 μL) was immunoprecipitated using His-tag antibody coated beads (Dynabeads His-tag Isolation & Pulldown, Invitrogen Dynal AS, Oslo, Norway) for 30 minutes at 4°C. The beads were washed 4× with Binding/Wash Buffer, and then His-Elution Buffer was added. For Western blot analysis, the immunoprecipitated proteins were loaded onto polyacrylamide gels and transferred onto polyvinylidene fluoride membranes. Membranes were blocked and incubated with rabbit polyclonal anti-6xHis antibody (Abcam; 1:5000 dilution) overnight at 4°C. Membranes were washed and incubated with secondary antibody (antirabbit antibody; 1:10000 dilutions; Cell signaling Inc, Danvers, MA) for 1 hour at room temperature. Bands were visualized by ECL Prime (GE Healthcare Life Sciences, Piscataway, NJ) and exposure to x-ray film. Band intensity was quantified using the Fluor-S MultiImager (Bio-Rad, Hercules, CA). Protein bands were trypsin digested and sequenced using Edman sequencing by the Mayo Proteomics Core Facility as previously described. 17, 19 Assays for ProBNP1-108, NT-ProBNP, and BNP Plasma proBNP1-108, NT-proBNP, and BNP levels were determined by immunoassays as previously described. [20] [21] [22] [23] ProBNP1-108 concentrations were determined using Bio-Rad proBNP1-108 assay with automated 2-step sandwich fluorescence immunoassay on the BioPlex 2200 analyzer (Bio-Rad). The proBNP1-108 intraand interassay coefficient variations using proBNP1-108 EDTA plasma pool were 6.0% and 7.7%, 5.4% and 6.7%, and 2.7% and 5.5%, at 140, 400, and 1900 pg/mL, respectively. The specifications of this assay indicate <0.05% cross-reactivity with BNP1-32 and NT-proBNP. NT-proBNP was measured on the Elecsys 2010 Analyzer (Roche Diagnostics; lower limit of detection, 5 µg/L with inter-and intra-assay coefficient variations 3.1% and 2.5%, respectively) and the cross-reactivity with proBNP1-108 and BNP1-32/3-32 were 30% and <2%, respectively. BNP was measured by the Shionoria assay method (inter-and intra-assay coefficient variations 7.2±1.7 µg/L and 8.0±1.4 µg/mL, respectively), which detects 82% of BNP1-32 and 100% of BNP3-32, and cross-reactivity with proBNP1-108 and NT-proBNP of <2% and <1%, respectively.
Cell Culture and cGMP Assay
Human embryonic kidney 293 cells were stably transfected with either human GC-A or GC-B using Lipofectamine (Invitrogen, Grand Island, NY). Transfected cells were maintained in Dulbecco Modified Eagle medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 U/mL streptomycin, and 250 μg/mL G418. Cells on 6-well plates were incubated in Hanks balanced salt solution (Invitrogen) containing 20 mmol/L HEPES, 0.1% BSA, and 0.5 mmol/L 3-isobutyl-1-methylxanthine (Sigma-Aldrich Co, St Lois, MO) and treated with BNP1-32 (Phoenix Pharmaceuticals, Inc, Burlingame, CA), proBNP1-108, immunoprecipitated proBNP1-108, or serum-treated (processed) proBNP1-108 for 10 minutes. Treated cells were lysed in 6% trichloroacetic acid and sonicated for 10 minutes. The samples were ether extracted 4 × in 4 volumes of ether, dried, and reconstituted in 300 µL cGMP assay buffer. The samples were assayed using a competitive RIA cGMP kit (Perkin-Elmer, Santa Clara, CA) as previously described. 24, 25 There is no cross-reactivity with atrial natriuretic peptide, BNP, C-type natriuretic peptide, endothelin, and <0.001% cross-reactivity with cAMP, GMP, GDP, ATP, and GTP.
Corin and DPPIV Assays
Serum corin or DPPIV levels were determined using commercially available ELISA (Quantikine, R&D Systems, Minneapolis, MN). In brief, samples and standards of recombinant human corin or DPPIV protein were added to microtiter plate wells precoated with antihuman corin or DPPIV antibody and incubated for 2 hours at room temperature. Each well was washed, then incubated with corin or DPPIV conjugate for 2 hours at room temperature. Wells were washed, and substrate solution was added. After incubation for 30 minutes at room temperature, the enzyme reactions were stopped. Human corin or DPPIV concentrations were determined by comparing with the standard curve. Intra-/interassay coefficient variations for corin and DPPIV were 2.9/3.6% and 5.6/8.5%, respectively.
Statistical Analysis
Descriptive statistics are reported as mean±SEM. Unpaired t test was performed for comparison between groups. Comparisons within a group in time course processing experiments were made by 1-way ANOVA followed by the Bonferroni multiple comparison post-test analysis when the global test was significant. Two-way ANOVA with main effects of time point and group was used to compare the results between normals and HF, followed by Bonferroni posttests. GraphPad Prism 5 (GraphPad Software, La Jolla, CA) and JMP 10 were used for the above calculations. Statistical significance was accepted as P<0.05.
Results

Circulating BNP Molecular Forms in Patients With HF Compared With Age-and Sex-Matched Normal Subjects
We examined circulating levels of proBNP1-108, NT-proBNP, and BNP in patients with HF (n=51) compared with normal subjects of similar age and sex, by selecting from the available group of normals using an age cutoff >65 (n=22; Table 1 ). All 3 molecular forms, including proBNP1-108, were significantly higher in HF when compared to normals, suggesting that proBNP1-108 production is enhanced or its processing is impaired in HF. Table 2 reports characteristics for normal (n=13) and patients with HF (n=14) used for the ex vivo proBNP1-108 processing and degradation studies, whereas Table I 
Patient Characteristics for Ex Vivo Study
ProBNP1-108 Processing in Human Serum From Normal Subjects Ex Vivo
We first examined proBNP1-108 processing in normal human serum treated with exogenous proBNP1-108. To identify processed BNP forms, 6 Histidines were tagged onto the C terminus so 6xHis antibody could be used to detect unprocessed proBNP1-108 (predicted molecular weight, 12.8 kD) and processed BNP1-32 (predicted molecular weight, 4.3 kD), but not processed NT-proBNP ( Figure 1A ). As we previously reported, 17 proBNP1-108 (≈12 kD) was processed at 5 minutes into a smaller molecular form (≈4 kD) in fresh serum from normal subjects ( Figure 1B) , which was confirmed as BNP1-32 and 3 to 32 by sequence analysis ( Figure 1B ). Processing to BNP1-32/BNP3-32 was not observed in samples pretreated with EDTA ( Figure 1B , 0 minutes). Figure 1B shows a representative Western blot for the time course processing of proBNP1-108 ≤180 minutes in normal serum. We examined 5 different time points: 0, 5, 15, 60, and 180 minutes. Densitometric analysis of these time points showed rapid processing with a decrease of 50% unprocessed proBNP1-108 at 5 minutes, then disappearing completely for 180 minutes ( Figure 1C ). Processed BNP (BNP1-32/3-32) was significantly increased at 5 minutes (P<0.0001 by 1-way ANOVA; Figure 1D ), remained elevated for 15 minutes, and then disappeared after 60 minutes ( Figure 1D ).
Densitometric Analysis of ProBNP1-108 Processing and Degradation in Fresh Serum From Normal Subjects Ex Vivo
ProBNP1-108 Processing and Degradation Profile in Normal Subjects Versus Patients With HF
We repeated our analyses to compare proBNP1-108 processing and degradation in patients with HF compared with normals ( Figure 2A-2C ). The overall time course of unprocessed proBNP1-108 was significantly different between normal subjects and patients with HF using 2-way ANOVA (P<0.0001; Figure 2B ). Unprocessed proBNP1-108 levels in HF at 5 and 15 minutes were significantly higher when compared with normals, suggesting that proBNP1-108 processing was delayed in HF when compared with normal subjects. BNP1-32/3-32 in patients with HF at 5 to 15 minutes were similar to normal subjects; however, it was significantly higher at 60 minutes than normals, and then decreased to levels similar to normal subjects at 180 minutes (P=0.005 by 2-way ANOVA; Figure 2C ), suggesting that BNP1-32/3-32 processing was completed but delayed in HF.
Corin and DPPIV Levels and in Normal Subjects Versus Patients With HF
We next examined circulating levels of processing enzyme corin and degrading enzyme DPPIV in our serum samples. In patients with HF, circulating corin levels tended to be lower, and DPPIV levels were significantly lower than in healthy subject serum ( Figure 2D and 2E) , which may contribute to the slower processing of proBNP1-108 and removal of BNP from HF serum.
Effect of Ejection Fraction on ProBNP1-108 Processing and Degradation
We performed a subanalysis of proBNP1-108 processing and degradation, dividing the HF samples into 2 groups: ejection fraction (EF) <50% or EF≥50% ( Figure 3A and 3B). The group with EF≥50% revealed significantly lower values of BNP1-32/3-32 when compared those with EF<50% ( Figure 3B ; P=0.006 by 2-way ANOVA); however, unprocessed proBNP1-108 was similar in both groups ( Figure 3A ; P=ns by 2-way ANOVA), suggesting that the EF≥50% group may have rapid and accelerated degradation of BNP1-32/3-32 within 5 minutes, whereas the EF<50% group may have delayed degradation of BNP1-32/3-32. Because of the significant age difference between the normal and HF groups, we performed additional subanalyses, dividing the normal group into 2 groups by median age (38 years) and found no significant difference in either unprocessed or processed forms by 2-way ANOVA (data not shown).
Effect of High Glycosylated and Nonglycosylated ProBNP1-108 Concentrations on ProBNP1-108 Processing and Degradation
To assess whether high circulating levels of proBNP1-108 interferes with His-tag proBNP1-108 processing and degradation ex vivo, we pretreated normal serum with 500 pg/ mL glycosylated or nonglycosylated proBNP1-108. Neither of these pretreatments affected His-tag proBNP1-108 processing or degradation ( Figure 3C and 3D) in normal serum, suggesting that the delay in processing and degradation seen in HF is not simply an overproduction of proBNP1-108, but may reflect a deficiency in enzyme level or activity. Densitometric analysis of unprocessed proBNP1-108 (A) and processed form (BNP1-32/3-32; B) at indicated times; EF<50% (closed square), EF≥50% (grayed circle), or normals (opened circle with breaking line). Values are mean±SEM. P values were shown in graphs analyzed by 2-way ANOVA with Bonferroni multiple comparison test. No significant difference between groups at indicated times, 2-way ANOVA with Bonferroni multiple comparison test. C and D, Ex vivo proBNP1-108 processing and degradation in normals with or without pretreatment with proBNP1-108. Representative WB for His-tag proBNP1-108 incubated in serum samples from normal subjects (n=4) for indicated times. Samples were pretreated with or without 500 pg/mL nonglycosylated proBNP1-108 (C) or glycosylated proBNP1-108 (D) before treatment with His-tag proBNP1-108. January 2015
cGMP Activity In Vivo in GC-A or GC-B Expressing Human Embryonic Kidney 293 Cells
We examined the cGMP-generating activity of proBNP1-108 and immunoprecipitated serum processed BNP forms in GC-A or GC-B expressing human embryonic kidney 293 cells. First, to verify activity levels of proBNP1-108 and BNP1-32, cells were treated with equimolar doses (10 −8 M) of synthetic BNP1-32 or synthetic proBNP1-108 for 10 minutes. As we have previously reported, BNP1-32 significantly increased cGMP production ( Figure 4A ), whereas proBNP1-108 significantly increased cGMP production, but to only 1/30th the level of BNP1-32 ( Figure 4A ) in GC-A-expressing cells. Neither proBNP1-108 nor BNP1-32 stimulated cGMP production in GC-B cells ( Figure 4A ).
Next, we assessed cGMP production with immunoprecipitated proteins from fresh, normal serum-treated with proBNP1-108 (10 −8 M) at 5 or 180 minutes, which may contain both unprocessed proBNP1-108 and processed proBNP1-108 (BNP1-32/3-32) and compared them with immunoprecipitated proBNP1-108 (10 −8 M) incubated in PBS as a control. ProBNP1-108 incubated in normal serum for 5 minutes stimulated significantly more cGMP production in GC-A cells when compared with either 180-minute serumtreated proBNP1-108 or proBNP1-108 in PBS ( Figure 4B ). ProBNP1-108 incubated in normal serum for 180 minutes did not stimulate cGMP production in GC-A cells ( Figure 4B ). ProBNP1-108 incubated in HF serum for 5 or 180 minutes generated cGMP levels similar to normals ( Figure 4B) . None of the samples stimulated cGMP production in GC-B cells ( Figure 4B ).
Discussion
The paradox of high circulating BNP levels in patients with HF has been a continuing source of consternation. Recent studies from our laboratory suggested that the increased BNP in patients with HF is in the form of the prohormone, proBNP1-108, which has little biological activity, suggesting that proBNP1-108 may not be processed in HF. 11, 13 This study demonstrates that exogenous proBNP1-108 processing occurs in the ex vivo human circulation of both normal and HF subjects, with degradation of all forms complete within 180 minutes. Delayed processing of proBNP1-108 was observed in HF when compared with normals. Furthermore, accelerated degradation of BNP1-32/3-32 was observed in HF with preserved EF (HFPEF), and delayed degradation of BNP1-32/3-32 was observed in HF with reduced EF (HFREF) relative to normals. The processed forms from both normal and HF samples were biologically active and generated cGMP through GC-A activation. Because of our surprise finding of delayed processing of BNP in HF serum, we examined the proBNP1-108-processing enzyme corin and the BNP-degrading enzyme DPPIV and found that both were reduced in HF when compared with those in normal serum. Our important new insights into BNP processing and activity in physiological and HF conditions include delayed but not absent proBNP1-108 processing in HF and retained cGMP-generating activity of mature BNP1-32 in patient samples with HF together with a reduction in 2 key BNPmodifying enzymes, corin and DPPIV, in HF.
Previously, we reported that proBNP1-108 was processed within 30 minutes in normal human serum and plasma. 17 Extending that study, we show that proBNP1-108 processing occurs rapidly in normal serum, with 50% of proBNP1-108 processed within the first 5 minutes and both active and unprocessed forms completely absent by 60 minutes. This suggests that the enzymes necessary to cleave proBNP1-108, generally thought to be furin or corin, are present and active in the normal circulation. Indeed, it has been reported that soluble corin is present in the circulation because of shedding of the membranebound form of corin, 26 and we have demonstrated the presence of corin in normal plasma both here and previously. 17 To date, there are no studies to confirm circulating forms of furin in human serum, and we were unable to detect furin in our serum samples (data not shown); however, soluble circulating forms of furin cannot be excluded. It is also possible that other, as yet undetermined enzymes process proBNP1-108 to active forms in normal human serum.
We and others have previously shown the presence of various BNP forms in the normal circulation, consisting of what was thought to be largely inactive forms (proBNP1-108, BNP4-32, and BNP5-32). 13, 14, 27 Similar to findings by Dickey and Potter, 28 we show that in fact, proBNP1-108 activates GC-A although with much less potency than BNP1-32. In addition, we show that active BNP1-32 is produced in normal serum, but it is rapidly used or degraded to the aforementioned smaller forms, implying that its presence in the serum is simply too short lived to be detected in normal sample assay situations. This hypothesis is supported by studies by Vanderheyden et al, 29 which showed that BNP1-32 is degraded into BNP3-32 by DPPIV in the circulation of either healthy or patients with HF.
We then hypothesized that patients with HF would demonstrate reduced processing of proBNP1-108 in HF serum as it has been reported that there may be impaired proBNP1-108 processing in HF 30 with decreased soluble corin levels. 31, 32 Indeed, proBNP1-108 was processed completely and degraded in HF serum, but the processing was delayed when compared with normals. There are several possible scenarios to explain our findings of delayed proBNP1-108 processing in HF: (1) reduced or delayed circulating proBNP1-108-processing enzyme presence or activity in HF. This theory is supported by the aforementioned studies of decreased soluble corin in HF. Indeed, corin levels trended lower in our HF samples; however, the contribution of furin or other as yet unknown proteases cannot be disregarded and additional studies are needed to understand the aberrant processing better; (2) excessive production of proBNP1-108 from the heart overwhelming the proBNP1-108 processing system in HF although here we show that high concentrations of proBNP1-108 added to our normal samples did not overwhelm the processing system, suggesting that under normal circumstances, the circulating enzymes are capable of dealing with excessive proBNP1-108 production; or (3) increased release of glycosylated versus nonglycosylated proBNP1-108, which is not cleaved by furin or corin, in HF. 4, 33 Although our current study shows that the addition of either nonglycosylated or glycosylated proBNP1-108 to normal serum does not delay proBNP1-108 processing, we cannot eliminate this possibility, which is supported by studies by Semenov et al 4 demonstrating that nonglycosylated proBNP1-108 made up <50% of the total proBNP1-108 of 23 patients with HF. If indeed too much glycosylated proBNP1-108 is being released into the circulation of patients with HF, or there is a defect in removing critical glycosylation for access to cleavage, exogenous nonglycosylated pro-NPs might be useful as administrative therapy in cardiovascular disease. Additional studies are needed.
To understand the degradation of BNP forms in HF better, we compared the levels of DPPIV in normal versus HF samples. DPPIV degrades BNP1-32 to BNP3-32 with high specificity, whereas it is a relatively poor and slow-degrading substrate for neprilysin. 5, 29 The level of DPPIV in normal versus patients with HF is not known although BNP3-32 levels, the product of DPPIV cleavage of BNP1-32, rise significantly in patients with HF. 29 We found a significantly lower level in our HF samples. The delayed processing of proBNP1-108 to BNP1-32 seen in our HF samples may mean less DPPIV is needed to handle the slower accumulation of BNP1-32. Conversely, DPPIV enzymatic activity was shown to be increased in the serum of patients with HF, 34 which may suggest that higher active but lower circulating levels of DPPIV are present in HF.
Among patients with HF, approximately half have preserved ejection fractions. The clinical manifestations of HFPEF and HFREF are similar; however, there are distinct differences in pathophysiology. 35 Therefore, we did a subanalysis of proBNP1-108 processing and degradation according to %EF. Interestingly, both patients with HFREF and HFPEF had delayed processing of proBNP1-108; however, HFPEF had accelerated (immediate) degradation of BNP1-32/3-32 and HFREF had delayed degradation of BNP1-32/3-32 compared with normals ( Figure 3A and 3B ), suggesting that the BNP-degradation system might differ in patients with HFPEF and HFREF. BNP1-32 is degraded by several enzymes, including, as mentioned previously, DPPIV, neprilysin, and insulin-degrading enzyme, and potentially yet unknown enzymes. Therapeutic blockade of BNP1-32-degrading enzymes, especially in HFPEF, may improve BNP1-32 availability and outcomes in this subgroup of patients with HF. Interestingly LCZ696, an angiotensin receptor neprilysin inhibitor, improved NT-proBNP levels and left atrial volume compared with valsartan, an angiotensin receptor blocker, in the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) study, which investigated the actions of LCZ696 in patients with HFPEF. 36 These favorable effects of LCZ696 may suggest that blocking accelerated degradation of BNP1-32 in patients with HFPEF will lead to better outcomes.
Finally, although we observed proBNP1-108 was cleaved in HF samples, it was possible that the cleaved products were inactive. Therefore, we examined these forms for functional activation and found that the HF processed BNP forms are functional. This may suggest that early or supplemental NP therapy would be helpful in meeting the demands of an impaired NP processing system in HF.
A limitation to the current study is that it was done in isolated serum, which may differ from the in vivo situation. Our ex vivo study reflects extracellular, circulating proBNP1-108/BNP1-32/BNP3-32 metabolism, and may not reflect the tissue/intracellular mechanism. ProBNP1-108 processing and activity may be influenced by other circulating materials, such as blood cells, cytokines, and enzymes present in the circulation or on cells found in whole blood circulation but not in isolated serum. Additional studies of proBNP1-108 processing in animal models are warranted. It is possible that the additional 6 histidine on the C terminus of proBNP1-108 may change its processing and degradation when compared with native proBNP1-108; however, these 6 histidines would not affect the comparison between normal and HF because we used the same His-tag proBNP1-108 for both groups. Finally, our population in the normal and HF ex vivo study differed in age because of the difficulty to collect fresh samples from age-matched normals. Our subanalysis showed that age did not have a strong effect on proBNP1-108 processing and degradation, but additional studies that are more closely matched in terms of age are required to confirm these findings.
In conclusion, proBNP1-108 is processed in the circulation of both normal and HF human subjects to biologically active cGMP-activating molecular forms. There is delayed processing and altered degradation of exogenous nonglycosylated proBNP1-108 in HF, providing new information about BNP molecular forms in the circulation of both normal and disease states.
